We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

165 hedge funds and large institutions have $514M invested in Meridian Bioscience Inc in 2017 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 68 increasing their positions, 43 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 43

8% less call options, than puts

Call options by funds: $541K | Put options by funds: $587K

8% less funds holding

Funds holding: 180165 (-15)

23% less capital invested

Capital invested by funds: $665M → $514M (-$151M)

28% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 36

Holders
165
Holders Change
-15
Holders Change %
-8.33%
% of All Funds
4.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
26
Increased
68
Reduced
43
Closed
36
Calls
$541K
Puts
$587K
Net Calls
-$46K
Net Calls Change
+$358K
Name Holding Trade Value Shares
Change
Change in
Stake
Tudor Investment Corp
76
Tudor Investment Corp
Connecticut
$688K +$396K +28,353 +132%
CCMINC
77
Cardinal Capital Management Inc (North Carolina)
North Carolina
$632K +$81.7K +5,846 +15%
NI
78
Numeric Investors
Massachusetts
$618K +$231K +16,500 +58%
PC
79
Polar Capital
United Kingdom
$613K
State of Tennessee, Department of Treasury
80
State of Tennessee, Department of Treasury
Tennessee
$547K +$88.4K +6,322 +19%
State Board of Administration of Florida Retirement System
81
State Board of Administration of Florida Retirement System
Florida
$535K
AG
82
Aperio Group
California
$506K +$315K +22,560 +160%
AIM
83
Alambic Investment Management
California
$490K +$496K +35,500 New
NCCM
84
Nine Chapters Capital Management
New Jersey
$490K +$496K +35,500 New
HCM
85
Hollencrest Capital Management
California
$489K
Manulife (Manufacturers Life Insurance)
86
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$466K +$62.5K +4,469 +15%
MLICM
87
Metropolitan Life Insurance Company (MetLife)
New York
$453K
Victory Capital Management
88
Victory Capital Management
Texas
$431K +$81.7K +5,844 +23%
Russell Investments Group
89
Russell Investments Group
United Kingdom
$424K -$35.2K -2,515 -8%
TPSF
90
Texas Permanent School Fund
Texas
$422K -$2.19K -157 -0.5%
GC
91
Guggenheim Capital
Illinois
$417K -$155K -11,061 -27%
Public Sector Pension Investment Board (PSP Investments)
92
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$398K
LAM
93
Lapides Asset Management
Connecticut
$391K +$396K +28,300 New
AIG
94
American International Group
New York
$354K -$69.4K -4,960 -16%
PCM
95
Prelude Capital Management
New York
$352K +$356K +25,492 New
Thrivent Financial for Lutherans
96
Thrivent Financial for Lutherans
Minnesota
$326K +$12.4K +890 +4%
ZCM
97
Zebra Capital Management
Connecticut
$322K -$190K -13,610 -37%
ASRS
98
Arizona State Retirement System
Arizona
$303K +$4.2K +300 +1%
MWAC
99
Mariner Wealth Advisors (Cincinnati)
Ohio
$289K +$8.38K +599 +3%
QC
100
Quadrature Capital
United Kingdom
$277K +$281K +20,107 New

VIVO Hedge Fund Activity: Q1 2017 in Review

165 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2017, worth a combined $514M — down 23% from $665M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of VIVO and 26 opened new positions — a net loss of 10 holders — while 43 trimmed existing stakes and 68 added.

The largest buyer was BlackRock, adding an estimated $71.8M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $17.8M sold.

  • 165 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2017, down from 180 in Q4 2016.
  • Funds reported $514M of Meridian Bioscience Inc stock for Q1 2017, down 23% quarter-over-quarter.
  • 26 funds opened new Meridian Bioscience Inc positions in Q1 2017 and 36 closed out, a net change of -10 holders.
  • The largest Meridian Bioscience Inc buyer in Q1 2017 was BlackRock, an estimated $71.8M added.
  • The largest Meridian Bioscience Inc seller in Q1 2017 was T. Rowe Price Associates, an estimated $17.8M sold.

Based on aggregated 13F filings for Q1 2017.